Study of 188Re ( V ) -DMSA for Treatment of Cancer - Rediolabeling and Biodistribution.
- Author:
Chang Soon KOH
;
Myung Chul LEE
;
June Key CHUNG
;
Dong Soo LEE
;
Young Ju KIM
;
Jae Min JEONG
;
Young Soo CHANG
- Publication Type:Original Article
- Keywords:
Therapeutic cancer radiopharmaceutical
- MeSH:
Animals;
Baths;
Hydrogen-Ion Concentration;
Mice;
Sarcoma;
Sarcoma 180;
Succimer;
Water
- From:Korean Journal of Nuclear Medicine
1998;32(1):81-88
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
The purpose of this study was to examine the radiolabeling and biodistribution of 188Re(V)-DMSA as a therapeutic cancer radiopharmaceutical. We made a DMSA kit(NaHC03 1.5 mg, meso-2,3-dimercaptosuccinic acid 1.0 mg L(+)-ascorbic acid 0.7mg, SnCl2 2H2O 0.34 mg, pH 2.9) for labeling with 188Re. In this kit, 188ReO4- 5 mCi/2 ml added and boiled at 100 degree C for 3 hr in water bath. The final pH adjusted to 7.5 with 7% NaHCO3 solution. We checked the labelling efficacy with TLC-SG(n-butanol : acetic acid:H2O = 3 : 2 : 3) and examined the stability both in room temperature and in serum at 37 degree C. Biodistribution(l, 3, 13, 24, 48 hr) of 188Re(V)-DMSA compound was evaluated in Sarcoma 180 tumor-bearing mice. Each labeling efficiency and stability at room temperature for 48 hours was over 98% and 95%, respectely. The stability in serum were 82%(6 hr) and 85%(48 hr). Tumor uptake of 188Re(V)-DMSA in Sarcoma 180- bearing mice were 0.66+/-0.15%(1 hr), 0.51+/-0.10%(3 hr), 0.19+/-0..05%(24 hr) and 0.13+/-0.02%(48 hr). These result are consistent with those of 99mTc(V)-DMSA which were reported previously In conclusion, 188Re(V)-DMSA may be a useful therapeutic radiopharmaceutical for treating some cancers and metastatic bone lesion.
